Minocycline in Clinically Isolated Syndromes (CIS)
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to demonstrate that 100 mg of oral minocycline twice daily reduces
the conversion of CIS to McDonald Criteria MS (McDMS) by an absolute 25% as compared to
placebo, over a 6 month follow-up period (primary outcome).
A key secondary outcome is to confirm that this early treatment benefit is maintained at two
years.